38.58
+1.14(+3.04%)
Currency In USD
| Previous Close | 37.44 |
| Open | 37.41 |
| Day High | 38.68 |
| Day Low | 36.92 |
| 52-Week High | 62.4 |
| 52-Week Low | 29.17 |
| Volume | 1.51M |
| Average Volume | 1.53M |
| Market Cap | 7.17B |
| PE | -10.78 |
| EPS | -3.58 |
| Moving Average 50 Days | 37.91 |
| Moving Average 200 Days | 44.28 |
| Change | 1.14 |
If you invested $1000 in Revolution Medicines, Inc. (RVMD) since IPO date, it would be worth $1,334.95 as of April 25, 2025 at a share price of $38.58. Whereas If you bought $1000 worth of Revolution Medicines, Inc. (RVMD) shares 3 years ago, it would be worth $1,733.15 as of April 25, 2025 at a share price of $38.58.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting
GlobeNewswire Inc.
Apr 01, 2025 8:05 PM GMT
REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced 11 oral and poster pres
Revolution Medicines to Participate in April 2025 Investor Conferences
GlobeNewswire Inc.
Mar 31, 2025 8:05 PM GMT
REDWOOD CITY, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith,
Revolution Medicines to Participate in March 2025 Investor Conferences
GlobeNewswire Inc.
Feb 24, 2025 9:05 PM GMT
REDWOOD CITY, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Golds